Search

Displaying results 2431 - 2440 of 10000 in total
  1. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. … [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]

    Synonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE
  2. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]

  3. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. … This indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518]

    Products: NUCALA 100 MG SUBKUTAN ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ, 1 ADET, NUCALA 100 MG SUBKUTAN ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ, 3 ADET
  5. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    [A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea. … FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803]

  6. Drug

    Esculin

    go.drugbank.com/drugs/DB13155
    Approved

    Esculin is found in barley. … ) and in daphnin (the dark green resin of Daphne mezereum).

  7. Drug

    Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10584
    ApprovedInvestigational

    Mixtures: dT-reduct „Mérieux“ - Injektionssuspension in einer Fertigspritze, Dt Polio Adsorbed - Sus Im
  8. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. … [L12123] It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated.

  9. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. … : it has been used as part of multi-agent chemotherapy.

  10. Drug

    Valrubicin

    go.drugbank.com/drugs/DB00385
    Approved

    It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder. … Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR.